The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | S | Sensory organs | |
| 2 | S01 | Ophthalmologicals | |
| 3 | S01E | Antiglaucoma preparations and miotics | |
| 4 | S01EX | Other antiglaucoma preparations |
| Code | Title | |
|---|---|---|
| S01EX01 | Guanethidine | |
| S01EX02 | Dapiprazole | |
| S01EX05 | ||
| S01EX06 | ||
| S01EX07 |
| Active Ingredient | Description | |
|---|---|---|
| Guanethidine |
Guanethidine is a antihypertensive drug. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. It is taken up by norepinephrine transporters. It becomes concentrated in norepinephrine transmitter vesicles, replacing norepinephrine in these vesicles. |
|
| Netarsudil |
Netarsudil, a Rho kinase inhibitor, is believed to reduce intraocular pressure (IOP) by increasing outflow of aqueous humor. Studies in animal and man suggest that the main mechanism of action is increased trabecular outflow. These studies also suggest that netarsudil lowers IOP by reducing episcleral venous pressure. |
|
| Omidenepag |
Omidenepag is a relatively selective EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown. Elevated IOP represents a major risk factor for glaucomatous field loss. |
|
| Ripasudil |
|
| Title | Information Source | Document Type | |
|---|---|---|---|
| OMLONTI Ophthalmic solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| RHOKIINSA Eye drops, solution | European Medicines Agency (EU) | MPI, EU: SmPC |
